proANP ELISA Assay Kit

$600.00

The Eagle Biosciences proANP (1-98) ELISA Assay KIT(enzyme-linked immunoassay kit) is intended for the quantitative determination of human, mouse, or rat proANP(1-98) in EDTA plasma, heparin plasma, serum, urine or cell culture supernatants. The proANP (1-98) ELISA Assay KIT is for research use only and not to be used in diagnostic procedures.

SKU: BI-20892 Categories: , ,

proANP ELISA Assay Kit

For Research Use Only

Size: 1×96 wells
Sensitivity: 0.05 nmol/L
Dynamic Range: 0.63 – 10 nmol/L
Incubation Time: 3.5 hours
Sample Type: plasma, urine, serum or cell culture supernatant
Sample Size: 10 µL
Species: Human, Mouse, Rat

Controls Included

Product Developed and Manufactured in Austria by Biomedica

Additional Information

Assay Background


Atrial natriuretic peptide is synthesized in atrial myocytes and is stored in secretory granules as a 126 amino acid prohormone. The most important stimulus for the release of the hormone into circulation is stretch of the myocyte fibres. On release the prohormone is split into equimolar amounts of the highly biologically active proANP (99-126), also known as a-ANP, and the N-terminal part proANP (1-98). a-ANP is rapidly cleared from the circulation with a half-life of 3-4 minutes. proANP (1-98) has a much longer half-life (60-120 min) which leads to significantly higher concentrations in blood compared to a-ANP. Thus, circulating levels of proANP (1-98) are less sensitive to the pulsatile secretion of ANP and may better reflect chronic levels of ANP secretion than the rapidly fluctuating levels of a-ANP. proANP is discussed as valuable marker for e.g. sepsis (Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Hoffmann U. et al., Clin. Lab. 2005;51 (7-8):373-9), or risk stratification in heart failure (Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. (Berger R. et al, European Journal of Clinical Investigation, 2005, 35 (1), 24-31)

Assay Principle


  1. All reagents and samples must be at room temperature (18-26°C) before use in the proANP (1-98) ELISA Assay Kit.
  2. Mark position for BLANK/STD/SAMPLE/CTRL (Blank/Standard/Sample/Control) on the protocol sheet.
  3. Take microtiter strips out of the bag, take a minimum of one well as Blank. Store unused strips with desiccant at 2-8°C in the bag. Strips are stable until expiry date stated on the label.
  4. Add 10 µl STD/SAMPLE/CTRL (Standards/Sample/Control) in duplicate into respective wells, except blank.
  5. Add 200 µl CONJ (Conjugate) into each well except blank, swirl gently.
  6. Cover tightly and incubate for 3 hrs at room temperature (18-26°C) in the dark.
  7. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer), remove remaining WASHBUF by hitting plate against paper towel after the latest wash.
  8. Add 200 µl SUB (Substrate) into each well.
  9. Incubate for 30 min at room temperature (18-26°C) in the dark.
  10. Add 50 µl STOP (Stop solution) into each well.
  11. Measure absorbance immediately at 450 nm with reference 620 nm, if available.

The assay also detects mouse and rat proANP (1-98)

Manual

Product Manual


Publications

References


  • Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Berger R. et al. European Journal of Clinical Investigation, 2005, 35 (1), 24-3
  • Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Hoffmann U. et al. Clin. Lab. 2005, 51(7-8), 373-9
  • isk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Jarai R. et al. European Heart Journal 2004, 26 (3), 250-256
  • Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Molhoek S. G. et al. Heart 2004, 90, 97-98
  • N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. Hall C. et al. Int. J. Cardiol. 2003 Jun, 89(2-3), 197-205
  • Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function. Otterstad JE et al., Eur Heart J 2002 Jul;23(13):1011-20

Related Resources Citing EagleBio Kits:

href=”https://www.sciencedirect.com/science/article/pii/S0735109701013833″>Stanek, B. et al. “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction” Journal of American Cardiology 2001; 38: 436-442.

Related News:
EagleBio Spotlight: BNP

EagleBio Spotlight: CNP

Interesting Study Highlighting Eagle Biosciences’ BNP Fragment ELISA Assay Kit 

Learn more about Vitamin ANP at Eagle Biosciences Biomarker Spotlight page dedicated to ANP here:

EagleBio Spotlight: ANP